Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07737496
PHASE1

A Study of HW243040 in Healthy Participants

Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

View on ClinicalTrials.gov

Summary

This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.

Official title: A Phase 1, Randomized, Double-Blind, Single-Center, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW243040 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

98

Start Date

2026-08-20

Completion Date

2027-05-31

Last Updated

2026-08-27

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

HW243040

HW243040 will be administered orally as a tablet.

DRUG

Placebo

Placebo will be administered orally as a tablet.

Locations (1)

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China